Manager, FP&A
$120k/y-$155k/y
Crescent Biopharma3 days ago
Highlight
OnsiteFull-timeSenior
Summary
Crescent Biopharma is seeking a Manager, FP&A to join their team in Waltham, MA. The role involves supporting corporate and program level planning, budgeting, and forecasting in a dynamic, science-driven environment.
About the Role
As a Manager of FP&A, you will lead the annual operating plan, long-range planning, and quarterly forecasting cycles across all functions. You will build driver-based financial models, support the implementation of ERP and planning tools, prepare financial reporting packages, manage cross-functional program budgets, and partner with various teams to ensure disciplined financial management.
About You
Required:
- Bachelor's degree in Finance, Accounting, Economics, or related field.
- 6+ years of progressive FP&A or Finance experience, ideally within biotech or pharma.
- Experience supporting R&D, clinical development, or other multiprogram environments.
- Demonstrated ability to partner cross-functionally and communicate complex concepts clearly.
- Highly analytical with strong attention to detail.
Preferred:
- Experience with biotech planning cycles (e.g., program budgeting, CRO/CMO forecasting).
- Familiarity with ERP systems, planning tools, and business intelligence platforms (e.g., NetSuite, Adaptive Insights).
- Proactive problem solver who anticipates needs.
- Strong interpersonal skills and business judgment.
Benefits
- Competitive compensation, including base salary, performance bonus, and equity.
- 100% employer-paid benefits package.
- Flexible PTO; two, one-week company-wide shutdowns each year.
- Commitment to professional development with access to resources, mentorship, and growth opportunities.
Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. Crescent’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com. Our pipeline originated at Paragon Therapeutics, a biotechnology company founded by Fairmount. Crescent is the fifth company launched to advance assets discovered at Paragon.
Waltham, MA